The Proof Behind The System Is The Real-World Evidence
Top healthcare companies trust us to help thousands of patients manage their medication schedule day after day.
A proven behavioral change system
Given the high level of investment to bring a medicine to market and then to ensure a patient is able to benefit from it, it’s critical that a patient has a positive medication onboarding experience. Aidia has consistently proven the ability, across disease states, to help patients start and stay on their medicine.
Patients benefit from additional prescriptions
Significantly improved retention regardless of payer
Consistently proven results across different therapies and disease states, published by top pharmacies and academic health centers.
Avella Pharmacy
UnitedHealth Group
26% increased time on therapy
per patient, per year.
Journal of Managed Care & Specialty Pharmacy (JMCP)
Avella Specialty Pharmacy, UnitedHealth Group
4.7 out of 5
overall patient satisfaction.
Journal of Acquired Immune Deficiency Syndromes (JAIDS)
Weill Cornell Clinical Trials Unit
+1 additional dose,
per week, per levels in the blood.
Avella Pharmacy
UnitedHealth Group
Avella Pharmacy
at the dose-level.
9% increase in fill rates
per patient, per year.
1-2 additional fills
of medication per patient per year.
“AdhereTech improves adherence and generates 1-2 additional fills of medication per patient per year, across multiple specialty medications and diseases.”
“AdhereTech improves adherence and generates 1-2 additional fills of medication per patient per year, across multiple specialty medications and diseases.”- “Patient feedback is overwhelmingly positive, with the average patient satisfaction rating at 4.7 out of 5.”
- “AdhereTech program continues to achieve stellar results for patients. One of the many benefits is that the program delivers additional support to patients or caregivers when it’s needed most, leading to a great patient experience.”
Journal of Managed Care & Specialty Pharmacy (JMCP)
Avella Specialty Pharmacy, UnitedHealth Group
Peer-reviewed
12.6% increased adherence
with more consistent dose-time behavior
compared with control group.
1 additional cycle
of medication taken compared with control
group over 6 months.
5 out of 5
(strongly agree) rating for ease of setup and
ease of use
- “[AdhereTech] demonstrated a significantly higher median adherence of 100% compared with the control arm median adherence of 87.4 (P=0.001).”
- “[AdhereTech patients] had more regulated behavior and took a greater proportion of doses during the optimal 2-hour dosing window (83% vs 22%; P<0.001).”
- “In addition to improved adherence, [AdhereTech patients] completed more cycles.”
Journal of Acquired Immune Deficiency Syndromes (JAIDS)
Weill Cornell Clinical Trials Unit
Peer-reviewed
1 additional dose per week
compared with control group.
- Patients using AdhereTech had optimal levels of medication in the blood “on the order of around one additional dose per week” vs patients not using AdhereTech.
- “Using an objective novel marker, intracellular tenofovir diphosphate by dried blood spot, demonstrates the best evidence of the use of [AdhereTech] to improve adherence.”
- Conducted and published by Dr. Roy Gulick, Chief of the Division of Infectious Diseases, Former Chairman of the FDA Antiviral Drugs Advisory Committee
Partner with us
Speak with a representative about how to support your organization’s patient populations.
The Aidia System can be easily and quickly implemented having been successfully used in more than 50 academic and pharma clinical trials
Source: Data on file. ADHD, Attention deficit hyperactivity disorder; HIV, human immunodeficiency virus.
My research colleagues and I conducted a randomized controlled trial of an educational intervention to improve glaucoma medication adherence. The patients using the Aidia Smart Bottle and messaging functions showed 20% higher adherence to the medication regimen compared to the control arm.
Given the adherence seen in the trial, my sense is that the AdhereTech Smart Bottle has a very positive impact on our study’s adherence rates.